Drug intelligence / Profile preview

Cudafol

Development stage: Phase 1
Lead developer: Cuda Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

Cudafol is an investigational improved formulation of the intravenous general anesthetic propofol, being developed by Cuda Pharmaceuticals (also referenced as Cuda Anesthetics) in collaboration with Ligand Pharmaceuticals to enhance propofol delivery characteristics, likely leveraging Ligand’s Captisol cyclodextrin-based excipient technology to improve solubility, stability, and/or tolerability compared with conventional lipid emulsion propofol products. It is intended for use as a general anesthetic and sedative, with pharmacologic effects mediated by potentiation of inhibitory GABAergic neurotransmission in the central nervous system in line with standard propofol mechanisms.

Brand names: Cudafol

Beyond the preview

Go deeper on Cudafol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cudafol.

Explore the full profile